It should be noted, however, that a recent clinical trial of a potent NFE2L2 inducer, bardoxolone methyl, known as the BEAM study, showed some improvements in eGFR of patients with type 2 diabetes with Chronic Kidney Disease (CKD) in the initial phase of the trial, but did not show any improvement in Phase III and had to be abandoned due to cardiovascular complications [54]. Here, NFE2L2 is linked to chronic kidney disease.